LSD can provide a treatment from the next generation of anxiety

A person’s acid journey can be anxiety for someone else. This is the confusing result from a new study that showed that LSD may have the ability to reduce anxiety. The results are the latest in a series of studies that indicate that the drug can help treat a group of mental health conditions.

The detailed second stage experience in this study was sponsored by a company called MindMed, which was developed as a royal form of LSD named MM-120. In experiment, people with general anxiety disorder who took LSD suffered a significant decrease in anxiety symptoms compared to imaginary therapy.

The company is already conducting larger experiments in the third stage of MM-120 for both anxiety and depression, with the expectations of the results of the next year.

“This study is a real turning point in the field of psychiatry,” said Maurizio Fava, head of the Ministry of Psychiatry at Mass GM and the deadly scientific advisor. statement. The team’s results were Published Thursday in Jama magazine.

Narcotic medicine

Anesthetic like LSD and Psilocybin (The active ingredient in magic mushrooms) may receive renewed scientific attention in recent years as possible treatments for mental health conditions. Regardless of causing feelings of euphoria and separation – mobiles that make them popular recreational medications – there is evidence that drug scientists interact positively with brain receptors and brain areas usually associated with anxiety, depression and other psychological states.

There are many LSD clinical trials to treat various current cases. But according to researchers standing behind this last study, this may be first for literature because it is a random experience controlled by an imaginary doses of MM120 for general anxiety disorder, without any additional treatment or other intervention.

LSD capabilities that reduce anxiety

The experiment included 198 people who were diagnosed with mild to extreme anxiety. Participants were given either a fake or one of the four doses of LSD. She was closely monitored for 12 hours (the LSD is the typical half -age of three to five hours, although it might take a day to completely erod it). Then the researchers followed the participants for 12 weeks.

By the fourth week, the participants who took a dose of 100 or 200 milligrams of LSD have been a much more decrease in anxiety symptoms compared to the place of imaginary drug. It is worth noting that the participants who took a smaller dose of 25 or 50 milligrams of LSD also benefited, but the difference was not a statistical sign.

For those who saw major changes, the improvement was often sustainable, as nearly half of the participants in 100 or 200 milligrams are considered to be reminded of their anxiety by week 12, compared to only 20 % of the controls.

There were a few moderate negative events in line with the well -known side effects of LSD, as some participants reported hallucinations or visual distortions, nausea and headache. Almost everyone who takes 100 milligrams or a high dose of visual changes.

LSD future as a treatment

The second stage experiments are mainly designed to confirm the integrity of the experimental drug. So these results should not be taken as evidence that LSD works as an anxiety medicine. But the data is definitely encouraging.

MINDMED launched three experiences of the third stage of MM-120, Two of them It is for generalized anxiety, and based on the previous data, participants will be granted a dose of 100 milligrams. These experiments, if successful, will provide the evidence for food and drug management and other organizers to consider LSD as a legitimate treatment.

However, narcotic medicine is still largely outside the main current. In 2019, the Food and Drug Administration (FDA) approved a derivative of the ketora (spravato spray in Johnson and Johnson) for treatment -resistant depression. But in 2024, it is Decline To agree to the treatment with the help of MDMA for post -shock disorder, pointing to the need for additional data for the third stage of the treatment sponsor, Lykos Therapeutics (Lykos is planning To do the required work). The MINDMED journey towards the FDA approval depends on the strength of their experiences, but this initial data indicates at least they have a promising path.